DQ 2556 

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins^[1][2].

DQ-2556 对革兰氏阳性菌有效，对耐甲氧西林葡萄球菌敏感 (MIC₉₀ = 1.56-3.13 μg/mL)，对链球菌高度有效 (MIC₉₀ ≤ 0.05 μg/mL)，对肠球菌活性有限 (MIC₉₀ = 50 μg/mL) DQ-2556 对革兰氏阴性菌有效，对大肠杆菌、肺炎克雷伯菌、奇异变形杆菌等的 MIC₉₀ 值不超过 0.05 μg/mL，对嗜血杆菌敏感。 DQ-2556 对流感嗜血杆菌和淋病奈瑟菌的 MIC90 为 0.1 μg/mL^[1][2]。 DQ-2556 对金黄色葡萄球菌、大肠杆菌和奇异变形杆菌的 MIC₉₀ 值相同或 ≤ 4 倍^[1][2]。 DQ-2556 (0.0008-12.5 μg，4 小时) 可诱导大肠杆菌形成丝状和球状结构，并在较高浓度下诱导细胞裂解^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

DQ-2556 (0.2 mL/只小鼠，皮下注射，单剂量) 对金黄色葡萄球菌、肺炎链球菌、大肠杆菌、肺炎克雷伯菌和粘质沙雷氏菌感染的 ED₅₀ 分别为 0.37、2.75、0.0091、0.23 和 0.029 mg/kg^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

541.56

C₂₂H₁₉N₇O₆S₂

102253-70-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fujimoto T, et al. In vitro activity of DQ-2556, a new cephalosporin. Antimicrob Agents Chemother. 1986 Oct;30(4):611-3.  [Content Brief]

  [2]. Ishida Y, et al. In vitro and in vivo activity of DQ-2556, a new cephalosporin. Chemotherapy. 1995 Jan-Feb;41(1):5-13.  [Content Brief]